Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 1/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757960 | 0.86 | KDM1A (0.46) | KMT2ARAD52PDE5AKDM1AADORA2A | |
| SCHEMBL10061504 | 0.78 | RAD52 (1.00) | KMT2ARAD52PDE5AKDM1ACYP1A2 | |
| SCHEMBL1758746 | 0.74 | KMT2A (0.57) | KMT2ARAD52KDM1ACYP1A2CYP3A4 | |
| SCHEMBL12646710 | 0.74 | KDM1A (0.44) | KMT2ARAD52KDM1ACYP1A2CYP3A4 | |
| SCHEMBL1758190 | 0.74 | ALDH1A1 (0.57) | KMT2ARAD52KDM1AADORA2ACYP1A2 | |
| SCHEMBL1758511 | 0.74 | KDM1A (0.44) | KMT2ARAD52PDE5AKDM1ACYP1A2 | |
| SCHEMBL14308497 | 0.74 | CYP1A2 (0.46) | KMT2ARAD52PDE5AKDM1ACYP1A2 | |
| SCHEMBL1758150 | 0.72 | CYP1A2 (0.61) | KMT2AKDM1AUSP1WDR48CYP1A2 | |
| SCHEMBL14318913 | 0.72 | KDM1A (0.42) | KMT2ARAD52PDE5AKDM1ACYP1A2 | |
| SCHEMBL1757986 | 0.72 | CSNK2A2 (0.42) | KMT2AKDM1ACYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633718-B1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-1633718-B1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943640-B2 | 3-Fluoro-2-(2-methylsulfanyl-phenyl)-quinolin-4-yl]-pyridin-4-yl-amine; modulating transforming growth factor (TGF) - beta; fibroproliferative diseases or diseases associated with fibrosis; cardiovascular, urogenital and gastrointestinal disorders; antihypotensive, -arthritic agents; angioplasty | MILLENIUM PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1633718-A4 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARM INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314939-B2 | Compositions and methods for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1633718-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050032835-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2004112710-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108656-A1 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-BETA | TGFBR1, TGFB1, TGFBR2 | KMT2A 4089/4885RAD52 4364/4885PDE5A 38/4885 |
| US-20050032835-A1 | Compositions and methods for inhibiting TGF-beta | TGFBR1, TGFB1, TGFBR2 | KMT2A 4089/4885RAD52 4364/4885PDE5A 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.